Some experts have said greater oversight of laboratory-developed tests will have negative impacts on cancer research and care ...
In April, the US Food and Drug Administration announced pipeline updates for several drugs intended to treat cancers.
Some researchers are working to sniff out fraud and restore integrity to their field.
The Mark Cuban Cost Plus Drug Company has the potential to reduce Medicare Part D spending for cancer drugs, data suggest.
Experts point to a clear incentivization of quantity, rather than quality, of research output — both with the publishing industry and academic institutions. Publishing articles is critical for success ...
Non-Hispanic Black patients with melanoma present with more advanced disease than non-Hispanic White patients, data suggest.
Trans-inclusive language can help clinicians promote accessible and equitable care in traditional women's health care spaces.
Merck has decided to discontinue the vibostolimab-pembrolizumab coformulation arm of the phase 3 KeyVibe-010 trial.
Adding perioperative nivolumab to neoadjuvant chemotherapy can improve outcomes in patients with non-small cell lung cancer (NSCLC), according to results from the CheckMate 77T trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results